drugset / Trial / NCT02907268

Botulinum Toxin A Single Blind Split-Face Randomized Pilot Study

NCT02907268

Phase 2 Completed 10 enrolled ICLS Dermatology & Plastic Surgery
RandomizedCrossoverSingle-blindTreatment

Summary

A 16-week single-blind, split-face, randomized study. Each patient served as their own control, receiving onabotulinumtoxinA and abobotulinumtoxinA randomized to either the left or right side of the face. Patients received intradermal BTXA injections at week 0 and intramuscular BTXA injections at week 2. The objective is to examine the effectiveness of intradermal botulinum toxin type A (BTXA) injection in improving skin texture and midface lift while reducing pore size and sebum production, as well as investigate the differences in effectiveness between onabotulinumtoxinA and abobotulinumtoxinA using intradermal and intramuscular injection methods.

Timeline

Start
2013-09
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic Other

Indications

No indication recorded.